Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
GERN's Cash-to-Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GERN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GERN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.99  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.94
GERN's Equity-to-Asset is ranked higher than
93% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GERN: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
GERN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.86 Max: 0.96
Current: 0.94
0.41
0.96
Piotroski F-Score: 3
Altman Z-Score: 17.55
Beneish M-Score: -3.66
WACC vs ROIC
21.29%
-149.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -497.34
GERN's Operating Margin % is ranked lower than
71% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. GERN: -497.34 )
Ranked among companies with meaningful Operating Margin % only.
GERN' s Operating Margin % Range Over the Past 10 Years
Min: -4069.18  Med: -2842.68 Max: -1.54
Current: -497.34
-4069.18
-1.54
Net Margin % -479.34
GERN's Net Margin % is ranked lower than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. GERN: -479.34 )
Ranked among companies with meaningful Net Margin % only.
GERN' s Net Margin % Range Over the Past 10 Years
Min: -4066.28  Med: -2767.01 Max: 0.13
Current: -479.34
-4066.28
0.13
ROE % -22.37
GERN's ROE % is ranked higher than
60% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GERN: -22.37 )
Ranked among companies with meaningful ROE % only.
GERN' s ROE % Range Over the Past 10 Years
Min: -60.98  Med: -39.36 Max: 0.03
Current: -22.37
-60.98
0.03
ROA % -21.23
GERN's ROA % is ranked higher than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GERN: -21.23 )
Ranked among companies with meaningful ROA % only.
GERN' s ROA % Range Over the Past 10 Years
Min: -53.81  Med: -35.38 Max: 0.03
Current: -21.23
-53.81
0.03
ROC (Joel Greenblatt) % -15292.83
GERN's ROC (Joel Greenblatt) % is ranked lower than
90% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GERN: -15292.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GERN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26858.87  Med: -3815.65 Max: 70.53
Current: -15292.83
-26858.87
70.53
3-Year Revenue Growth Rate 57.40
GERN's 3-Year Revenue Growth Rate is ranked higher than
88% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. GERN: 57.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GERN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.5  Med: -24.6 Max: 192.4
Current: 57.4
-81.5
192.4
3-Year EBITDA Growth Rate -14.50
GERN's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GERN: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GERN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -6.3 Max: 13.3
Current: -14.5
-35.9
13.3
3-Year EPS without NRI Growth Rate -14.10
GERN's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GERN: -14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GERN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -100  Med: -13.2 Max: 23.9
Current: -14.1
-100
23.9
GuruFocus has detected 3 Warning Signs with Geron Corp $GERN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GERN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GERN Guru Trades in Q1 2016

Jim Simons 453,480 sh (New)
Paul Tudor Jones 104,800 sh (+620.62%)
Joel Greenblatt 466,859 sh (+55.63%)
First Eagle Investment 159,700 sh (unchged)
» More
Q2 2016

GERN Guru Trades in Q2 2016

Jim Simons 461,580 sh (+1.79%)
First Eagle Investment 159,700 sh (unchged)
Paul Tudor Jones 88,300 sh (-15.74%)
Joel Greenblatt 33,232 sh (-92.88%)
» More
Q3 2016

GERN Guru Trades in Q3 2016

Paul Tudor Jones 169,600 sh (+92.07%)
Jim Simons 515,380 sh (+11.66%)
Joel Greenblatt Sold Out
First Eagle Investment 144,700 sh (-9.39%)
» More
Q4 2016

GERN Guru Trades in Q4 2016

First Eagle Investment 144,700 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 46,700 sh (-72.46%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CNCE, NAS:PDLI, NAS:MRUS, AMEX:BTX, NAS:BOLD, NAS:SYRS, NAS:AGEN, NAS:OTIC, NAS:SGMO, NAS:IDRA, NAS:BSTC, NAS:ARNA, OTCPK:ZLDPF, NAS:CRIS, NAS:RXDX, NAS:AKBA, NAS:AVDL, NAS:VYGR, NAS:MACK, NAS:BLCM » details
Traded in other countries:GON.Germany,
Headquarter Location:USA
Geron Corp is a biopharmaceutical company that supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen.

Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.

Top Ranked Articles about Geron Corp

Geron 2017 Annual Meeting of Stockholders to be Held on May 9
Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results

Conference Call Scheduled for 4:30 p.m. ET Today, March 1

MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported financial results for the fourth quarter and year ended December 31, 2016 and recent events. Fourth Quarter and Year-End 2016 Results For each of the fourth quarter of 2016 and 2015, the company reported a net loss of $8.5 million, or $(0.05) per share. For 2016, the company reported a net loss of $29.5 million, or $(0.19) per share, compared to net income of $46,000, or $0.00 per share, for 2015. The company ended 2016 with $129.1 million in cash and investments. Revenues for the fourth quarter of 2016 were $94,000 compared to $220,000 for the comparable 2015 period. Revenues for 2016 were $6.2 million compared to $36.4 million for 2015. Revenues for 2016 included the full recognition of an upfront payment of $5.0 million from Janssen Pharmaceuticals, Inc. under a license agreement for certain rights to the company’s specialized oligonucleotide backbone chemistry and novel amidates. Revenues for 2015 included the full recognition of the $35.0 million upfront payment from Janssen Biotech, Inc. (Janssen) as collaboration revenue upon the company’s transfer of the imetelstat license rights and completion of technology transfer-related activities outlined under the imetelstat collaboration agreement with Janssen. The upfront cash payment was received in December 2014 and recorded as deferred revenue at that time. Total operating expenses for each of the fourth quarter of 2016 and 2015 were $8.9 million. Total operating expenses for 2016 were $36.8 million compared to $36.9 million for 2015. Operating expenses for 2015 included restructuring charges of $1.3 million in connection with the company’s organizational resizing announced in March 2015. Research and development expenses for the fourth quarter of 2016 were $4.1 million compared to $4.0 million for the comparable 2015 period. Research and development expenses for 2016 were $18.0 million compared to $17.8 million for 2015. The increase in research and development expenses in 2016 compared to 2015 primarily reflected the net result of higher costs for the company’s proportionate share of clinical development expenses under the imetelstat collaboration with Janssen, partially offset by reduced personnel-related costs resulting from the March 2015 organizational resizing and lower costs for the manufacturing of imetelstat drug product. General and administrative expenses for the fourth quarter of 2016 were $4.8 million compared to $4.9 million for the comparable 2015 period. General and administrative expenses for 2016 were $18.8 million compared to $17.8 million for 2015. The increase in general and administrative expenses in 2016 compared to 2015 primarily reflected the net result of higher non-cash stock-based compensation expense and an increased allocation of facilities and other overhead costs to general and administrative activities, partially offset by lower consulting and legal costs. Interest and other income for the fourth quarter of 2016 was $321,000 compared to $196,000 for the comparable 2015 period. Interest and other income for 2016 was $1.2 million compared to $677,000 for 2015. The increase in interest and other income for 2016 compared to 2015 primarily reflected higher yields on the company’s marketable securities portfolio. “In 2016, the imetelstat program progressed with the ongoing clinical trials in patients with myelofibrosis and myelodysplastic syndromes being conducted by Janssen, as well as through a range of preclinical and translational studies in collaboration with academic scientists around the world,” said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer. “2017 will be another important year for imetelstat. We expect Janssen to conduct the second internal reviews of data from IMbark and IMerge to inform Janssen’s decisions regarding further development plans for the drug, including prospects around dosing in IMbark and opening the Phase 3 part of IMerge. We expect Janssen’s decision-making to occur in the second quarter of 2017.” 2016 EVENTS SUMMARY Imetelstat Clinical Development by Janssen In January, the first patient was dosed in IMerge, a Phase 2/3 clinical trial to evaluate imetelstat in transfusion dependent patients with IPSS low or intermediate-1 risk myelodysplastic syndromes (MDS) who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent (ESA). IMerge is the second clinical trial to be initiated and conducted by Janssen under the terms of the exclusive worldwide imetelstat license and collaboration agreement between Geron and Janssen. The first, IMbark, was designed to evaluate two dose levels of imetelstat in patients with intermediate-2 or high risk myelofibrosis (MF) who have relapsed after or are refractory to prior treatment with a JAK inhibitor.
 In September, Janssen completed planned internal reviews of data from IMbark and IMerge. As a result of these data reviews, both trials are continuing in order to obtain additional and more mature data. While patients remaining in the treatment phase of IMbark and IMerge continue to be dosed with imetelstat, new patient enrollment in both trials is suspended until completion of the second internal data reviews.   Publications and Presentations In March, Blood Cancer Journal published clinical safety and efficacy data on imetelstat from patients with a form of MDS known as refractory anemia with ringed sideroblasts (MDS-RARS) enrolled as part of the Mayo Clinic Pilot Study. The data included nine patients enrolled in the study cohort, classified as having either IPSS intermediate-1 or intermediate-2 risk disease. Three of the eight (37.5%) patients who were dependent on red blood cell transfusions at study entry became transfusion independent for at least eight weeks. The median duration of transfusion independence was 28 weeks (range: nine weeks to 37 weeks).
 At the American Association for Cancer Research annual meeting in April, non-clinical data on imetelstat were presented describing:

- Results from a study in which imetelstat treatment of acute myeloid leukemia (AML) cell lines enhanced the effects of hypomethylating agents currently used for the treatment of AML.

- Results from non-clinical studies that provide further evidence of potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials.

At the American Society of Hematology annual meeting in December, data related to the imetelstat program were presented describing:

- Results from a non-clinical study showing that treatment with imetelstat prolonged overall survival of AML xenografts derived from nine out of 15 individual patient samples compared to saline-treated controls.

- An analysis of treatment patterns and outcomes of patients with MF from two United States medical health insurance claims databases showing a median overall survival of seven months among patients who failed or discontinued frontline ruxolitinib.

- Telomere length dynamics from the prior Geron-sponsored proof-of-concept study in patients with essential thrombocythemia (ET) showing that in 10 out of 13 patients, telomere length in granulocytes was higher after nine months of treatment with imetelstat and the change correlated with the reduction of JAK2V617F mutational burden, suggesting that imetelstat may suppress neoplastic clones and favor recovery of normal hematopoiesis in these patients.

- A preliminary investigation suggesting that imetelstat treatment reduces the number of leukemia progenitor cells detected in bone marrow from xenograft models of chronic myeloid leukemia in blast crisis. These publications and posters are available through the Publications page in the R&D section of Geron’s website (www.geron.com). Intellectual Property In July, U.S. patent 9,375,485 related to imetelstat was issued by the U.S. Patent and Trademark Office with claims covering the use of telomerase inhibitor compounds, including imetelstat, for alleviating at least one symptom of myelofibrosis or myelodysplastic syndromes, including chronic myelomonocytic leukemia, which is expected to remain in force until at least March 2033. FUTURE EVENTS
In the first quarter of 2017, Janssen initiated the process for the second internal data reviews for both IMbark and IMerge. The company expects the outcomes from the second internal data reviews, regulatory considerations and the totality of other program information, including the evolving treatment landscapes in MF and MDS, to inform Janssen’s decisions regarding future development plans for imetelstat.
 Data from the Phase 2 part of IMerge is expected to be submitted by Janssen for presentation at a medical conference in 2017. Conference Call and Webcast At 4:30 p.m. ET on March 1, 2017, Geron’s management will host a conference call to discuss the company’s fourth quarter and annual results as well as recent company events. Participants can access the conference call live via telephone dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 53505663. A live audio-only webcast is also available through the Investors section of our website at www.geron.com or at http://edge.media-server.com/m/p/ouvh9xwx. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through April 1, 2017. About Geron Geron is a biopharmaceutical company supporting the clinical stage development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.  Use of Forward-Looking Statements Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding: (i) continued conduct by Janssen of IMbark or IMerge and/or any further development of imetelstat; (ii) Janssen obtaining additional or more mature data from IMbark or IMerge; (iii) that Janssen will conduct any additional or further data reviews of IMbark or IMerge, and the timing of such data reviews; (iv) potential outcomes of any data reviews conducted by Janssen; (v) the safety and efficacy of imetelstat; (vi) financial projections and expectations; (vii) patent coverage for imetelstat; (viii) pre-clinical data; and (ix) other statements that are not historical facts, constitute forward-looking statements. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (i) whether imetelstat will succeed in IMbark and IMerge by overcoming all of the clinical safety and efficacy, technical, scientific, manufacturing and regulatory challenges; (ii) whether Janssen decides to continue or terminate its development of imetelstat; (iii) Janssen’s ability to collect additional and more mature data from current clinical trials of imetelstat; (iv) whether Janssen continues to conduct IMerge or IMbark; (v) whether health authorities permit the further development of imetelstat; (vi) Geron’s dependence on Janssen for the development, regulatory approval, manufacture and commercialization of imetelstat, including the risks that if Janssen were to breach or terminate the collaboration agreement or otherwise fail to successfully develop and commercialize imetelstat and in a timely manner, or at all, Geron would not obtain the anticipated financial and other benefits of the collaboration agreement with Janssen and the clinical development or commercialization of imetelstat could be delayed or terminated; (vii) whether imetelstat is safe and efficacious, and whether any future efficacy or safety results may cause the benefit/risk profile of imetelstat to become unacceptable; (viii) the fact that Geron may not receive any milestone, royalty or other payments from Janssen because Janssen may terminate the collaboration agreement for any reason; (ix) the ability of Geron and Janssen to protect and maintain intellectual property rights for imetelstat; (x) whether pre-clinical data has any correlation to clinical results; and (xi) the need for future capital. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors,” including Geron’s annual report on Form 10-K for the year ended December 31, 2016. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. Financial table follows. GERON CORPORATION
CONDENSED STATEMENTS OF OPERATIONS  UNAUDITED
Three Months Ended
December 31,Year Ended
December 31,(In thousands, except share and per share data) 2016  2015  2016  2015      Revenues:    Collaboration revenue$— $— $— $35,000 License fees and royalties 94  220  6,162  1,371 Total revenues 94  220  6,162  36,371      Operating expenses:    Research and development 4,120  3,982  18,047  17,831 Restructuring charges â€”  â€”  â€”  1,306 General and administrative 4,755  4,882  18,761  17,793 Total operating expenses 8,875  8,864  36,808  36,930 Loss from operations (8,781) (8,644) (30,646) (559)     Unrealized gain on derivatives â€”  â€”  â€”  16 Interest and other income 321  196  1,192  677 Interest and other expense (22) (20) (83) (88)Net (loss) income$(8,482)$(8,468)$(29,537)$46      Net (loss) income per share:    Basic$(0.05)$(0.05)$(0.19)$0.00 Diluted$(0.05)$(0.05)$(0.19)$0.00 Shares used in computing net (loss) income per share:    Basic 159,147,351  158,378,421  159,045,644  158,036,162 Diluted 159,147,351  158,378,421  159,045,644  162,663,894                                                                                                                             

CONDENSED BALANCE SHEETS   December 31, December 31,(In thousands) 2016 2015   Current assets:    Cash, cash equivalents and restricted cash$13,078$21,515  Current marketable securities 102,035 92,524  Other current assets 999 1,853Total current assets 116,112 115,892   Noncurrent marketable securities 13,954 32,661Property and equipment, net 183 207 $130,249$148,760   Current liabilities$7,869$6,634Stockholders’ equity 122,380 142,126 $130,249$148,760     
CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.37
GERN's PB Ratio is ranked higher than
59% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GERN: 3.37 )
Ranked among companies with meaningful PB Ratio only.
GERN' s PB Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.74 Max: 12.12
Current: 3.37
1.07
12.12
PS Ratio 65.88
GERN's PS Ratio is ranked lower than
79% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. GERN: 65.88 )
Ranked among companies with meaningful PS Ratio only.
GERN' s PS Ratio Range Over the Past 10 Years
Min: 11.3  Med: 119.07 Max: 620
Current: 65.88
11.3
620
EV-to-EBIT -9.33
GERN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GERN: -9.33 )
Ranked among companies with meaningful EV-to-EBIT only.
GERN' s EV-to-EBIT Range Over the Past 10 Years
Min: -1775.3  Med: -4 Max: 5293.3
Current: -9.33
-1775.3
5293.3
EV-to-EBITDA -9.35
GERN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GERN: -9.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
GERN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2063.2  Med: -4.1 Max: 3733.2
Current: -9.35
-2063.2
3733.2
Current Ratio 14.76
GERN's Current Ratio is ranked higher than
89% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GERN: 14.76 )
Ranked among companies with meaningful Current Ratio only.
GERN' s Current Ratio Range Over the Past 10 Years
Min: 3.67  Med: 7.17 Max: 21.82
Current: 14.76
3.67
21.82
Quick Ratio 14.76
GERN's Quick Ratio is ranked higher than
89% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GERN: 14.76 )
Ranked among companies with meaningful Quick Ratio only.
GERN' s Quick Ratio Range Over the Past 10 Years
Min: 3.67  Med: 7.17 Max: 21.82
Current: 14.76
3.67
21.82
Days Sales Outstanding 28.14
GERN's Days Sales Outstanding is ranked higher than
79% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. GERN: 28.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
GERN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.1  Med: 137.65 Max: 304.85
Current: 28.14
12.1
304.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.80
GERN's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GERN: -6.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GERN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.8  Med: -15.35 Max: -2.1
Current: -6.8
-37.8
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.84
GERN's Price-to-Net-Cash is ranked higher than
73% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. GERN: 3.84 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GERN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.71  Med: 4.12 Max: 119.3
Current: 3.84
1.71
119.3
Price-to-Net-Current-Asset-Value 3.78
GERN's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. GERN: 3.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GERN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65  Med: 4.07 Max: 70.18
Current: 3.78
1.65
70.18
Price-to-Tangible-Book 3.34
GERN's Price-to-Tangible-Book is ranked higher than
67% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GERN: 3.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GERN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 3.61 Max: 19.03
Current: 3.34
1.26
19.03
Price-to-Median-PS-Value 0.55
GERN's Price-to-Median-PS-Value is ranked higher than
81% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GERN: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GERN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.56 Max: 7.61
Current: 0.55
0.1
7.61
Earnings Yield (Greenblatt) % -10.73
GERN's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GERN: -10.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GERN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.95  Med: 0.3 Max: 0.4
Current: -10.73
-11.95
0.4

More Statistics

Revenue (TTM) (Mil) $6.16
EPS (TTM) $ -0.19
Beta3.18
Short Percentage of Float23.85%
52-Week Range $1.81 - 3.27
Shares Outstanding (Mil)159.16
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Geron 2017 Annual Meeting of Stockholders to be Held on May 9 Apr 25 2017 
Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Apr 10 2017 
Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time Apr 09 2017 
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting Apr 05 2017 
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results Mar 01 2017 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 

More From Other Websites
Geron 2017 Annual Meeting of Stockholders to be Held on May 9 Apr 25 2017
Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron Apr 11 2017
Geron’s Imetelstat Reports Positive Interim Data Apr 10 2017
Why Geron Corporation Stock Is Surging Higher Today Apr 10 2017
Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by... Apr 10 2017
Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time Apr 09 2017
ETFs with exposure to Geron Corp. : April 7, 2017 Apr 07 2017
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : April 6, 2017 Apr 06 2017
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting Apr 05 2017
ETFs with exposure to Geron Corp. : March 27, 2017 Mar 27 2017
Today's Research Reports on Stocks to Watch: Geron and Galena Biopharma Mar 20 2017
Geron Corp. :GERN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Geron Corp. :GERN-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Geron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : March 15, 2017 Mar 15 2017
Edited Transcript of GERN earnings conference call or presentation 1-Mar-17 9:30pm GMT Mar 03 2017
Geron Announces Presentation at American Association for Cancer Research Annual Meeting Mar 02 2017
Geron Corporation Reports Fourth Quarter and Annual 2016 Financial Results Mar 01 2017
Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2016 Financial Results Feb 22 2017
4 Stocks Under $4 That Could Double Feb 09 2017
Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)